



---

# Summary Prescription Drug Costs Report

Small Group & Individual Markets, Plan Year 2024

09/04/2025

---

## Table of Contents

<b>Cover Letter .....</b>	<b>3</b>
Reporting process.....	3
Requested data elements.....	3
Data limitations .....	4
<b>Small Group Market – Summary Prescription Drug Costs Reporting .....</b>	<b>5</b>
Part 1: Most Frequently Prescribed Drugs .....	5
Part 2: Most Costly Prescription Drugs as a Portion of Total Annual Expenditures.....	6
Part 3: Prescription Drugs that have Caused the Greatest Increase in Total Spending .....	7
Part 4: Inquiry & Response Items .....	8
<b>Individual Market – Summary Prescription Drug Costs Reporting .....</b>	<b>9</b>
Part 1: Most Frequently Prescribed Drugs .....	9
Part 2: Most Costly Prescription Drugs as a Portion of Total Annual Expenditures.....	10
Part 3: Prescription Drugs that have Caused the Greatest Increase in Total Spending .....	11
Part 4: Inquiry & Response Items .....	12
<b>Prescription Drug Data Collection Templates .....</b>	<b>13</b>
D3: Top 50 Most Frequently Prescribed Drugs .....	13
D4: Top 50 Most Costly Prescription Drugs.....	14
D5: Top 50 Prescription Drugs by Spending Increase.....	15
<b>Prescription Drug Cost Supplemental Form .....</b>	<b>16</b>

## Prescription Drug Costs

In 2019, Minnesota amended Minn. Stat. Chapter 62K.07 to increase visibility into the cost of providing prescription drug benefits in individual and small group market health plans. Each carrier offering a prescription drug benefit in its individual or small group health plans is required to include certain prescription drug data in the applicable rate filing. Commerce, in consultation with Health, is required to release a summary of the data reported.

### Reporting process

The Department provided instructions and a template for reporting data. Beginning in 2023, the department decided to reduce duplicative work by the individual and small group carriers by using the reporting and/or underlying data from the Consolidated Appropriations Act's (CAA) Prescription Drug Data Collections (RxDC). Carriers were encouraged to limit the data provided in the RxDC templates to only reflect data for Minnesota and the applicable market segment. Each health carrier was required to submit their prescription drug cost reporting information to the Department via SERFF within the applicable rate filing or binder by June 3, 2024.

The Department received reports from all eight carriers filing to offer plans in the small group market and from all six carriers filing to offer plans in the individual market.

The data in the attached summary reports is drawn from the information as submitted by the carriers. Within each summary report, ranking is determined based on the aggregate sum of reports of a specific Rx Drug Code.

### Requested data elements

The following data was requested from each health carrier filing to offer individual or small group health plans in 2026:

1. The 50 most frequently prescribed drugs in 2024 (RxDC D3).
2. The 50 most costly prescribed drugs as a portion of total annual expenditures in 2024 (RxDC D4).
3. The 50 prescription drugs that caused the greatest increase in total spending in 2024 (RxDC D5).
4. The projected impact of the cost of prescription drugs on 2026 premium rates.
5. Whether any health plan offered requires enrollees to pay cost-sharing on covered prescription drugs in an amount greater than the health plan would pay for the drug absent the applicable cost-sharing and after any rebate amount.
6. Whether third-party payments, such as drug manufacturer discounts or coupons that cover all or a portion of the enrollee's cost-sharing, apply towards the enrollee's cost-sharing obligations.

Copies of the reporting templates are included beginning on page 13.

## Data limitations

- The Department has reported data as submitted by the carriers and cannot guarantee its accuracy.
- Certain prescription drug names may appear multiple times within the same summary report due to differences in manufacturer, form, dosage, packaging, etc. by RxDC code.
- While the Department provided instruction, methods for ranking prescription drugs may have varied by carrier due to interpretation.
- The data in the summary reports has not been independently audited.

## Small Group Market - Summary Prescription Drug Costs Reporting - Part 1

### Top 25 Most Frequently Prescribed Drugs in Plan Year 2024

Rank	Drug Code (RxDC)	Drug Name	Total Number of Prescriptions
1	R19913020101001	semaglutide [Ozempic]	14,477
2	R00004350101004	albuterol [Ventolin]	11,385
3	R26017230101001	tirzepatide [Mounjaro]	7,464
4	R15456530101001	empagliflozin [Jardiance]	7,324
5	R13644300101001	apixaban [Eliquis]	5,224
6	R03273610101001	adalimumab [Humira]	5,107
7	R16571280201003	influenza A virus antigen   influenza B virus antigen [Fluarix]	4,172
8	R00514280101002	insulin aspart human [NovoLog]	4,141
9	R24682310101005	SARS-CoV-2 (COVID-19) vaccine mRNA spike protein [Comirnaty 2024-2025]	3,919
10	R15512910101001	dulaglutide [Trulicity]	3,645
11	R18763760101001	dupilumab [Dupixent]	2,979
12	R07008100101001	lisdexamfetamine [Vyvanse]	2,792
13	R11141950101001	rivaroxaban [Xarelto]	2,715
14	R16571280201005	influenza A virus antigen   influenza B virus antigen [Flucelvax]	2,604
15	R00198310201001	budesonide   formoterol [Symbicort]	2,454
16	R02747830101002	insulin glargine [Lantus]	2,267
17	R02747830101003	insulin glargine [Semglee]	1,843
18	R00105820101005	levothyroxine [Synthroid]	1,834
19	R20588460101001	galcanezumab [Emgality]	1,623
20	R02145550101001	etanercept [Enbrel]	1,555
21	R16571280201008	influenza A virus antigen   influenza B virus antigen [Fluzone]	1,533
22	R14885640101001	dapagliflozin [Farxiga]	1,506
23	R16656840101001	evolocumab [Repatha]	1,474
24	R22823070101001	rimegepant [Nurtec]	1,437
25	R00411260202001	fluticasone   vilanterol [Breo]	1,352

Small Group Market - Summary Prescription Drug Costs Reporting - Part 2

**Most Costly Prescription Drugs as a Portion of  
Total Annual Expenditures in Plan Year 2024**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Annual Cost of Drug
1	R03273610101001	adalimumab [Humira]	\$15,282,440
2	R08470830101001	ustekinumab [Stelara]	\$13,264,333
3	R21660400101001	risankizumab [Skyrizi]	\$11,380,106
4	R19913020101001	semaglutide [Ozempic]	\$10,993,320
5	R18763760101001	dupilumab [Dupixent]	\$7,545,950
6	R22569510301001	elexacaftor   ivacaftor   tezacaftor [Trikafta]	\$6,425,945
7	R02145550101001	etanercept [Enbrel]	\$6,035,421
8	R26017230101001	tirzepatide [Mounjaro]	\$5,422,716
9	R21960920101001	upadacitinib [Rinvoq]	\$4,539,123
10	R15456530101001	empagliflozin [Jardiance]	\$4,256,530
11	R15997880101001	secukinumab [Cosentyx]	\$4,112,337
12	R13644300101001	apixaban [Eliquis]	\$3,439,606
13	R17450990101001	ixekizumab [Taltz]	\$3,425,155
14	R19996600302001	bictegravir   emtricitabine   tenofovir alafenamide [Biktarvy]	\$3,251,888
15	R15512910101001	dulaglutide [Trulicity]	\$2,964,042
16	R19468250101001	abemaciclib [Verzenio]	\$2,839,281
17	R19285880101001	guselkumab [Tremfya]	\$2,067,770
18	R03582570101001	tolvaptan [Jynarque]	\$2,047,150
19	R11141950101001	rivaroxaban [Xarelto]	\$1,839,151
20	R02762370201001	emtricitabine   tenofovir alafenamide [Descovy]	\$1,834,701
21	R14927270101001	apremilast [Otezla]	\$1,739,219
22	R16032960101001	lenvatinib [Lenvima]	\$1,666,138
23	R03423690101000	lenalidomide [Revlimid]	\$1,654,249
24	R07119420101001	eltrombopag [Promacta]	\$1,630,272
25	R19913020101003	semaglutide [Wegovy]	\$1,482,402

Small Group Market - Summary Prescription Drug Costs Reporting - Part 3

**Prescription Drugs that have Caused the  
Greatest Increase in Total Spending in Plan Year 2024**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Increase in Annual Spending
1	R21660400101001	risankizumab [Skyrizi]	\$4,109,424
2	R26017230101001	tirzepatide [Mounjaro]	\$3,687,957
3	R19913020101001	semaglutide [Ozempic]	\$3,639,708
4	R08470830101001	ustekinumab [Stelara]	\$3,326,432
5	R18763760101001	dupilumab [Dupixent]	\$2,150,880
6	R21960920101001	upadacitinib [Rinvoq]	\$1,876,855
7	R17450990101001	ixekizumab [Taltz]	\$1,461,077
8	R19468250101001	abemaciclib [Verzenio]	\$1,398,781
9	R15997880101001	secukinumab [Cosentyx]	\$1,391,522
10	R07119420101001	eltrombopag [Promacta]	\$1,136,990
11	R15456530101001	empagliflozin [Jardiance]	\$1,076,916
12	R03423690101000	lenalidomide [Revlimid]	\$1,024,168
13	R02145550101001	etanercept [Enbrel]	\$920,024
14	R14927270101001	apremilast [Otezla]	\$893,452
15	R00441570101001	cladribine [Mavenclad]	\$844,056
16	R16032960101001	lenvatinib [Lenvima]	\$842,222
17	R19285880101001	guselkumab [Tremfya]	\$746,886
18	R03273610101001	adalimumab [Humira]	\$726,839
19	R13644300101001	apixaban [Eliquis]	\$713,411
20	R17215600101001	osimertinib [Tagrisso]	\$709,845
21	R22569510301001	elexacaftor   ivacaftor   tezacaftor [Trikafta]	\$701,947
22	R15975820101001	olaparib [Lynparza]	\$685,461
23	R20498730101001	ivosidenib [Tibsovo]	\$653,495
24	R03023790101001	omalizumab [Xolair]	\$619,243
25	H25878920201003	nirmatrelvir   ritonavir [Paxlovid]	\$612,019

Small Group Market - Summary Prescription Drug Costs Reporting - Part 4 Inquiry and Response Items		
Question:	Range	
On average, what portion (on both a percentage and dollar PMPM basis) of your plan year 2026 premium rates is associated with covering expected prescription drug claims?	11.60% to 24.92% \$71.01 to \$160.00 PMPM	
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Do any health plans offered by the health carrier require enrollees to pay cost-sharing on any covered prescription drugs including deductibles, co-payments, or coinsurance in an amount that is greater than the amount the enrollee's health plan would pay for the drug absent the applicable enrollee cost-sharing and after accounting for any rebate amount?	5	3
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Does the health carrier prohibit third-party payments including manufacturer drug discounts or coupons that cover all or a portion of an enrollee's cost-sharing requirements including deductibles, co-payments, or coinsurance from applying toward the enrollee's cost-sharing obligations under the enrollee's health plan?	0	8



# Individual Market - Summary Prescription Drug Costs Reporting - Part 1

## Top 25 Most Frequently Prescribed Drugs in Plan Year 2024

Rank	Drug Code (RxDC)	Drug Name	Total Number of Prescriptions
1	R00004350101004	albuterol [Ventolin]	11,458
2	R19913020101001	semaglutide [Ozempic]	10,224
3	R24682310101005	SARS-CoV-2 (COVID-19) vaccine mRNA spike protein [Comirnaty 2024-2025]	6,947
4	R15456530101001	empagliflozin [Jardiance]	6,871
5	R26017230101001	tirzepatide [Mounjaro]	6,778
6	R13644300101001	apixaban [Eliquis]	6,445
7	R16571280201003	influenza A virus antigen   influenza B virus antigen [Fluarix]	6,320
8	R15512910101001	dulaglutide [Trulicity]	5,073
9	R03273610101001	adalimumab [Humira]	4,579
10	R16571280201005	influenza A virus antigen   influenza B virus antigen [Flucelvax]	4,382
11	R00514280101002	insulin aspart human [NovoLog]	4,061
12	R19996600302001	bictegravir   emtricitabine   tenofovir alafenamide [Biktarvy]	3,360
13	DLTLXVX6Z	covid-19 mrna virus vaccine [Spikevax Covid-19 Vaccine]	2,957
14	R11141950101001	rivaroxaban [Xarelto]	2,918
15	R16571280201008	influenza A virus antigen   influenza B virus antigen [Fluzone]	2,539
16	R00105820101005	levothyroxine [Synthroid]	2,340
17	R19868210101001	varicella zoster virus glycoprotein E [Shingrix]	2,231
18	R18763760101001	dupilumab [Dupixent]	2,186
19	R02747830101001	insulin glargine [Basaglar]	1,851
20	R16571280201001	influenza A virus antigen   influenza B virus antigen [Afluria]	1,840
21	R02747830101002	insulin glargine [Lantus]	1,831
22	R20588460101001	galcanezumab [Emgality]	1,610
23	R02145550101001	etanercept [Enbrel]	1,609
24	R16656840101001	evolocumab [Repatha]	1,556
25	R02762370201001	emtricitabine   tenofovir alafenamide [Descovy]	1,518

**Individual Market - Summary Prescription Drug Costs Reporting - Part 2**

**Most Costly Prescription Drugs as a Portion of  
Total Annual Expenditures in Plan Year 2024**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Annual Cost of Drug
1	R03273610101001	adalimumab [Humira]	\$13,944,296
2	R19996600302001	bictegravir   emtricitabine   tenofovir alafenamide [Biktarvy]	\$13,819,494
3	R08470830101001	ustekinumab [Stelara]	\$11,008,567
4	R21660400101001	risankizumab [Skyrizi]	\$8,886,400
5	R22569510301001	elexacaftor   ivacaftor   tezacaftor [Trikafta]	\$7,570,229
6	R19913020101001	semaglutide [Ozempic]	\$6,783,003
7	R02145550101001	etanercept [Enbrel]	\$5,705,277
8	R18763760101001	dupilumab [Dupixent]	\$5,421,351
9	R26017230101001	tirzepatide [Mounjaro]	\$4,525,835
10	R13644300101001	apixaban [Eliquis]	\$4,320,990
11	R15512910101001	dulaglutide [Trulicity]	\$4,152,203
12	R19468250101001	abemaciclib [Verzenio]	\$3,719,862
13	R15456530101001	empagliflozin [Jardiance]	\$3,632,690
14	R15997880101001	secukinumab [Cosentyx]	\$3,585,461
15	R02762370201001	emtricitabine   tenofovir alafenamide [Descovy]	\$3,495,043
16	R21960920101001	upadacitinib [Rinvoq]	\$3,367,088
17	R03423690101001	lenalidomide [Revlimid]	\$3,219,113
18	R17450990101001	ixekizumab [Taltz]	\$2,195,310
19	R11141950101001	rivaroxaban [Xarelto]	\$1,947,072
20	R19897940101001	emicizumab [Hemlibra]	\$1,696,979
21	R19285880101001	guselkumab [Tremfya]	\$1,646,260
22	R18739160101001	ribociclib [Kisqali]	\$1,602,785
23	R13062840402001	cobicistat   elvitegravir   emtricitabine   tenofovir alafenamide [Genvoya]	\$1,452,145
24	R03582570101001	tolvaptan [Jynarque]	\$1,443,359
25	R00040830101000	estradiol	\$1,406,898

**Individual Market - Summary Prescription Drug Costs Reporting - Part 3**  
**Prescription Drugs that have Caused the**  
**Greatest Increase in Total Spending in Plan Year 2024**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Increase in Annual Spending
1	R19996600302001	bictegravir   emtricitabine   tenofovir alafenamide [Biktarvy]	\$8,715,865
2	R08470830101001	ustekinumab [Stelara]	\$4,654,415
3	R03273610101001	adalimumab [Humira]	\$4,350,859
4	R21660400101001	risankizumab [Skyrizi]	\$3,872,497
5	R19913020101001	semaglutide [Ozempic]	\$3,162,708
6	R26017230101001	tirzepatide [Mounjaro]	\$3,004,090
7	R18763760101001	dupilumab [Dupixent]	\$2,658,932
8	R15456530101001	empagliflozin [Jardiance]	\$2,281,375
9	R15512910101001	dulaglutide [Trulicity]	\$2,199,578
10	R02145550101001	etanercept [Enbrel]	\$2,043,165
11	R13644300101001	apixaban [Eliquis]	\$1,800,972
12	R15997880101001	secukinumab [Cosentyx]	\$1,657,761
13	R22569510301001	elexacaftor   ivacaftor   tezacaftor [Trikafta]	\$1,456,947
14	R03423690101001	lenalidomide [Revlimid]	\$1,413,626
15	R21960920101001	upadacitinib [Rinvoq]	\$1,378,296
16	R02762370201001	emtricitabine   tenofovir alafenamide [Descovy]	\$903,871
17	R15975820101001	olaparib [Lynparza]	\$796,060
18	R18739160101001	ribociclib [Kisqali]	\$796,025
19	R21106050101001	caplacizumab [Cabliivi]	\$759,567
20	R03582570101001	tolvaptan [Jynarque]	\$735,193
21	R11141950101001	rivaroxaban [Xarelto]	\$642,726
22	DM1JQ8B7X3QUI	nirmatrelvir-ritonavir [Paxlovid]	\$635,904
23	R16563280201001	sacubitril   valsartan [Entresto]	\$620,830
24	R19897940101001	emicizumab [Hemlibra]	\$609,245
25	R02747830101001	insulin glargine [Basaglar]	\$587,437

Individual Market - Summary Prescription Drug Costs Reporting - Part 4 Inquiry and Response Items		
Question:	Range	
On average, what portion (on both a percentage and dollar PMPM basis) of your plan year 2026 premium rates is associated with covering expected prescription drug claims?	14.53% to 28.46% \$51.06 to \$205.44 PMPM	
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Do any health plans offered by the health carrier require enrollees to pay cost-sharing on any covered prescription drugs including deductibles, co-payments, or coinsurance in an amount that is greater than the amount the enrollee's health plan would pay for the drug absent the applicable enrollee cost-sharing and after accounting for any rebate amount?	6	0
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Does the health carrier prohibit third-party payments including manufacturer drug discounts or coupons that cover all or a portion of an enrollee's cost-sharing requirements including deductibles, co-payments, or coinsurance from applying toward the enrollee's cost-sharing obligations under the enrollee's health plan?	0	6

## Prescription Drug Data Collection Templates

### D3 Top 50 Most Freq Brand Drugs

[illegible]

## D4 Top 50 Most Costly Drugs

[illegible]

## D5 Top 50 Drugs by Spending Increase

Issuer or TPA Name	Issuer or TPA EIN	State	Market Segment	Drug Name	Drug Code	Spending Increase Rank	Number of Paid Claims	Number of Members with a Paid Claim	Number of Dosage Units	Total Spending	Total Cost Sharing	Manufacturer Cost-Sharing Assistance

Prior Year Number of Paid Claims	Prior Year Number of Members with a Paid Claim	Prior Year Number of Dosage Units	Prior Year Total Spending	Prior Year Total Cost Sharing	Prior Year Manufacturer Cost-Sharing Assistance	Dollar Increase in Total Spending

## Prescription Drug Cost Supplemental Form

**Issuer Name:**

**Market:**

**SERFF Tracking Number:**

**Plan Year:**

This template is required for all issuers in the Individual and Small Group Markets.

**1. On average, what portion (on both a percentage and dollar PMPM basis) of your plan year 2026 premium rates is associated with covering expected prescription drug claims?**

**2. Do any health plans offered by the health carrier require enrollees to pay cost-sharing on any covered prescription drugs including deductibles, co-payments, or coinsurance in an amount that is greater than the amount the enrollee's health plan would pay for the drug absent the applicable enrollee cost-sharing and after accounting for any rebate amount?**

☐ Yes    ☐ No



**3. Does the health carrier prohibit third-party payments including manufacturer drug discounts or coupons that cover all or a portion of an enrollee's cost-sharing requirements including deductibles, co-payments, or coinsurance from applying toward the enrollee's cost-sharing obligations under the enrollee's health plan?**

☐ Yes    ☐ No